These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 25253894)
1. Modeling tumor heterogeneity and predicting effective combined therapies through computational optimization algorithms. Azuaje FJ Proc Natl Acad Sci U S A; 2014 Oct; 111(41):E4287. PubMed ID: 25253894 [No Abstract] [Full Text] [Related]
2. Reply to Azuaje: Predicting effective combined therapies for heterogeneous tumors. Zhao B; Hemann MT; Lauffenburger DA Proc Natl Acad Sci U S A; 2014 Oct; 111(41):E4288. PubMed ID: 25253893 [No Abstract] [Full Text] [Related]
3. Intratumor heterogeneity alters most effective drugs in designed combinations. Zhao B; Hemann MT; Lauffenburger DA Proc Natl Acad Sci U S A; 2014 Jul; 111(29):10773-8. PubMed ID: 25002493 [TBL] [Abstract][Full Text] [Related]
4. [General principles of cancer chemotherapy]. Orzechowska-Juzwenko K Pol Tyg Lek; 1983 Dec 19-26; 38(51-52):1675-8. PubMed ID: 6679091 [No Abstract] [Full Text] [Related]
5. Sensitivity of latent cancer to chemotherapy. Schrek R Med Hypotheses; 1992 Jul; 38(3):215-6. PubMed ID: 1513276 [TBL] [Abstract][Full Text] [Related]
7. [Criteria for the determination of the efficacy of solid cancer chemotherapy]. Saito T Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):626-34. PubMed ID: 3954385 [No Abstract] [Full Text] [Related]
8. Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. Frei E; Miller D; Clark JR; Fallon BG; Ervin TJ Recent Results Cancer Res; 1986; 103():1-5. PubMed ID: 3738192 [No Abstract] [Full Text] [Related]
9. Computational modeling of tumor response to vascular-targeting therapies--part I: validation. Gevertz JL Comput Math Methods Med; 2011; 2011():830515. PubMed ID: 21461361 [TBL] [Abstract][Full Text] [Related]
10. Implications of certain cell kinetic and biological parameters for preoperative chemotherapy. Hill BT Recent Results Cancer Res; 1986; 103():41-53. PubMed ID: 3526475 [No Abstract] [Full Text] [Related]
11. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Roukos DH Expert Rev Proteomics; 2012 Aug; 9(4):349-53. PubMed ID: 22967071 [No Abstract] [Full Text] [Related]
13. The cancer stem cell gamble. Kaiser J Science; 2015 Jan; 347(6219):226-9. PubMed ID: 25593170 [No Abstract] [Full Text] [Related]
14. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Mailankody S; Prasad V Oncologist; 2016 Sep; 21(9):1031-2. PubMed ID: 27401893 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for metastatic disease. Carter SK Symp Fundam Cancer Res; 1983; 36():397-410. PubMed ID: 6382516 [No Abstract] [Full Text] [Related]
18. The influence of microenvironmental factors during cancer therapy. Durand RE In Vivo; 1994; 8(5):691-702. PubMed ID: 7727714 [TBL] [Abstract][Full Text] [Related]
19. Concepts for the treatment of tumor metastasis. Griswold DP; Schabel FM; Dykes DJ; Trader MW; Laster WR Symp Fundam Cancer Res; 1983; 36():389-96. PubMed ID: 6382515 [No Abstract] [Full Text] [Related]